About Michael Nelson
Form D filings for Intrommune Therapeutics from 2018 to 2024 list Michael Nelson as president and director.
Michael Nelson first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Nelson in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Michael Nelson works with at each company, as listed on that company's latest Form D.
Intrommune Therapeutics, Inc. · Form D, Jan 22, 2024